FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017445056> ?p ?o ?g. }

• W2017445056 endingPage "147" @default.
• W2017445056 startingPage "140" @default.
• W2017445056 abstract "Background The issue of whether saturated fats and trans fats are superior predictors of all-cause death and cardiovascular disease than n-3 polyunsaturated fatty acids, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), remains a matter of contention. Furthermore, few studies have examined the relationship between fatty acids and the outcomes of cardiovascular disease (CVD) in Asian populations. The aim of this study was to compare the effectiveness of various plasma fatty acids as predictors for all-cause death and CVD events in an ethnic Chinese population. Methods This study assembled a community-based prospective cohort, comprising 1833 participants (60.6 ± 10.5 yrs, 44.5% women) who underwent a comprehensive evaluation of fatty acids in blood using gas chromatography. None of the subjects had a history of CVD at the time of recruitment. Results A total of 568 individuals died and 275 individuals developed CVD during the follow-up period (median of 9.6 years; interquartile range of 8.9–10.5 years). Following adjustment for established cardiovascular risk factors, the relative risk of all-cause death in the highest quartile, compared with the lowest quartile, was 1.33 for saturated fats (95% confidence interval [CI], 1.01–1.75, test for trend, P = 0.015), 1.71 for trans fats (95% CI, 1.27–2.31, test for trend, P = 0.0003), 0.77 for EPA (95% CI, 0.59–1.00, test for trend, P = 0.048), and 0.89 for DHA (95% CI, 0.68–1.18, test for trend, P = 0.354). Similar patterns were observed for CVD events. Trans fats presented the largest area under the receiver operator characteristic curve (0.740, 95% CI, 0.716–0.766) for the prediction of all-cause death. A mutually adjusted two-marker model indicated that saturated fats and trans fats were significant predictors of all-cause death and CVD; however, the other fatty acids were not. In addition, trans fats presented the greatest improvement in net reclassification for all-cause death (7.7%, P = 0.003), followed by EPA (3.8%, P = 0.033). Saturated fats presented the greatest improvement in net reclassification for CVD events (5.6%, P = 0.039). Conclusions Our data provides strong evidence to support that plasma saturated fats and trans fats can predict all-cause death and CVD more effectively than other fatty acid markers." @default.
• W2017445056 created "2016-06-24" @default.
• W2017445056 creator A5015061276 @default.
• W2017445056 creator A5022217980 @default.
• W2017445056 creator A5033321414 @default.
• W2017445056 creator A5064383488 @default.
• W2017445056 creator A5066049666 @default.
• W2017445056 creator A5075177822 @default.
• W2017445056 creator A5078946821 @default.
• W2017445056 date "2013-09-01" @default.
• W2017445056 modified "2023-10-18" @default.
• W2017445056 title "Comparison of predictive performance of various fatty acids for the risk of cardiovascular disease events and all-cause deaths in a community-based cohort" @default.
• W2017445056 cites W1518563622 @default.
• W2017445056 cites W1560062315 @default.
• W2017445056 cites W1942583428 @default.
• W2017445056 cites W1965144287 @default.
• W2017445056 cites W1966714873 @default.
• W2017445056 cites W1969777279 @default.
• W2017445056 cites W1973609606 @default.
• W2017445056 cites W1980689873 @default.
• W2017445056 cites W1985967126 @default.
• W2017445056 cites W2007576400 @default.
• W2017445056 cites W2045234581 @default.
• W2017445056 cites W2065567352 @default.
• W2017445056 cites W2070161901 @default.
• W2017445056 cites W2097301645 @default.
• W2017445056 cites W2099360170 @default.
• W2017445056 cites W2100764470 @default.
• W2017445056 cites W2102150307 @default.
• W2017445056 cites W2103762686 @default.
• W2017445056 cites W2111475404 @default.
• W2017445056 cites W2112316706 @default.
• W2017445056 cites W2113969989 @default.
• W2017445056 cites W2117730841 @default.
• W2017445056 cites W2121943809 @default.
• W2017445056 cites W2126271291 @default.
• W2017445056 cites W2132894645 @default.
• W2017445056 cites W2142347023 @default.
• W2017445056 cites W2143915650 @default.
• W2017445056 cites W2148309495 @default.
• W2017445056 cites W2151373895 @default.
• W2017445056 cites W2152441052 @default.
• W2017445056 cites W2156924995 @default.
• W2017445056 cites W2157995113 @default.
• W2017445056 cites W2165270724 @default.
• W2017445056 cites W2167345535 @default.
• W2017445056 cites W2170521351 @default.
• W2017445056 cites W2328176404 @default.
• W2017445056 doi "https://doi.org/10.1016/j.atherosclerosis.2013.06.015" @default.
• W2017445056 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23958266" @default.
• W2017445056 hasPublicationYear "2013" @default.
• W2017445056 type Work @default.
• W2017445056 sameAs 2017445056 @default.
• W2017445056 citedByCount "25" @default.
• W2017445056 countsByYear W20174450562014 @default.
• W2017445056 countsByYear W20174450562015 @default.
• W2017445056 countsByYear W20174450562016 @default.
• W2017445056 countsByYear W20174450562017 @default.
• W2017445056 countsByYear W20174450562018 @default.
• W2017445056 countsByYear W20174450562019 @default.
• W2017445056 countsByYear W20174450562021 @default.
• W2017445056 countsByYear W20174450562022 @default.
• W2017445056 countsByYear W20174450562023 @default.
• W2017445056 crossrefType "journal-article" @default.
• W2017445056 hasAuthorship W2017445056A5015061276 @default.
• W2017445056 hasAuthorship W2017445056A5022217980 @default.
• W2017445056 hasAuthorship W2017445056A5033321414 @default.
• W2017445056 hasAuthorship W2017445056A5064383488 @default.
• W2017445056 hasAuthorship W2017445056A5066049666 @default.
• W2017445056 hasAuthorship W2017445056A5075177822 @default.
• W2017445056 hasAuthorship W2017445056A5078946821 @default.
• W2017445056 hasBestOaLocation W20174450562 @default.
• W2017445056 hasConcept C119060515 @default.
• W2017445056 hasConcept C126322002 @default.
• W2017445056 hasConcept C188816634 @default.
• W2017445056 hasConcept C19038510 @default.
• W2017445056 hasConcept C201903717 @default.
• W2017445056 hasConcept C2776091944 @default.
• W2017445056 hasConcept C2777171753 @default.
• W2017445056 hasConcept C2908647359 @default.
• W2017445056 hasConcept C44249647 @default.
• W2017445056 hasConcept C543025807 @default.
• W2017445056 hasConcept C55493867 @default.
• W2017445056 hasConcept C68443243 @default.
• W2017445056 hasConcept C71924100 @default.
• W2017445056 hasConcept C72563966 @default.
• W2017445056 hasConcept C86803240 @default.
• W2017445056 hasConcept C99454951 @default.
• W2017445056 hasConceptScore W2017445056C119060515 @default.
• W2017445056 hasConceptScore W2017445056C126322002 @default.
• W2017445056 hasConceptScore W2017445056C188816634 @default.
• W2017445056 hasConceptScore W2017445056C19038510 @default.
• W2017445056 hasConceptScore W2017445056C201903717 @default.
• W2017445056 hasConceptScore W2017445056C2776091944 @default.
• W2017445056 hasConceptScore W2017445056C2777171753 @default.
• W2017445056 hasConceptScore W2017445056C2908647359 @default.
• W2017445056 hasConceptScore W2017445056C44249647 @default.
• W2017445056 hasConceptScore W2017445056C543025807 @default.

• next